+57.7%
GEV vs MRNA
+511.3%
-453.6%
-24.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | -2.2% | +2.2% | 0.0% |
| 7D | +3.3% | +5.5% | -2.2% | +3.2% |
| 30D | -7.5% | +158.7% | -166.2% | -10.2% |
| 3M | -2.2% | +182.1% | -184.3% | -7.2% |
| 6M | +12.1% | +151.8% | -139.7% | +7.0% |
| YTD | +44.4% | +393.6% | -349.2% | +27.6% |
| 1Y | +57.7% | +499.5% | -441.8% | +37.4% |
| All | +57.7% | +511.3% | -453.6% | +37.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling